The unleashing of the immune system in COVID-19 and sepsis: the calm before the storm?

Salvatore Bellinvia; Christopher J. Edwards; Matteo Schisano; Paolo Banfi; Matteo Fallico; Paolo Murabito

doi:10.1007/s00011-020-01366-6

The unleashing of the immune system in COVID-19 and sepsis: the calm before the storm?

Salvatore Bellinvia, Christopher J. Edwards, Matteo Schisano, Paolo Banfi, Matteo Fallico, Paolo Murabito

Research output: Contribution to journal › Article › peer-review

Abstract

The novel coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is sorely testing health care systems and economies around the world and is rightly considered as the major health emergency in a century. Despite the course of the disease appearing to be mild in many cases, a significant proportion of symptomatic patients develop pneumonia requiring hospitalisation or progress to manifest respiratory complications leading to intensive care treatment. Potential interventions for SARS-CoV2-associated pneumonia are being tested, some of which holding promise, but as of today none of these has yet demonstrated outstanding efficacy in treating COVID-19. In this article, we discuss fresh perspectives and insights into the potential role of immune dysregulation in COVID-19 as well as similarities with systemic inflammatory response in sepsis and the rationale for exploring novel treatment options affecting host immune response.

Original language	English
Journal	Inflammation Research
DOIs	https://doi.org/10.1007/s00011-020-01366-6
Publication status	E-pub ahead of print - May 1 2020

Keywords

Checkpoint inhibitors
Covid-19
Cytokine storm
Immune dysregulation
Inflammatory receptors
Sepsis

ASJC Scopus subject areas

Immunology
Pharmacology

Access to Document

10.1007/s00011-020-01366-6

Fingerprint Dive into the research topics of 'The unleashing of the immune system in COVID-19 and sepsis: the calm before the storm?'. Together they form a unique fingerprint.

Cite this

@article{e7034bd06d8b44269055636fd427de6e,

title = "The unleashing of the immune system in COVID-19 and sepsis: the calm before the storm?",

abstract = "The novel coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is sorely testing health care systems and economies around the world and is rightly considered as the major health emergency in a century. Despite the course of the disease appearing to be mild in many cases, a significant proportion of symptomatic patients develop pneumonia requiring hospitalisation or progress to manifest respiratory complications leading to intensive care treatment. Potential interventions for SARS-CoV2-associated pneumonia are being tested, some of which holding promise, but as of today none of these has yet demonstrated outstanding efficacy in treating COVID-19. In this article, we discuss fresh perspectives and insights into the potential role of immune dysregulation in COVID-19 as well as similarities with systemic inflammatory response in sepsis and the rationale for exploring novel treatment options affecting host immune response.",

keywords = "Checkpoint inhibitors, Covid-19, Cytokine storm, Immune dysregulation, Inflammatory receptors, Sepsis",

author = "Salvatore Bellinvia and Edwards, {Christopher J.} and Matteo Schisano and Paolo Banfi and Matteo Fallico and Paolo Murabito",

year = "2020",

month = may,

day = "1",

doi = "10.1007/s00011-020-01366-6",

language = "English",

journal = "Inflammation Research",

issn = "1023-3830",

publisher = "Birkhauser Verlag Basel",

}

TY - JOUR

T1 - The unleashing of the immune system in COVID-19 and sepsis

T2 - the calm before the storm?

AU - Bellinvia, Salvatore

AU - Edwards, Christopher J.

AU - Schisano, Matteo

AU - Banfi, Paolo

AU - Fallico, Matteo

AU - Murabito, Paolo

PY - 2020/5/1

Y1 - 2020/5/1

N2 - The novel coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is sorely testing health care systems and economies around the world and is rightly considered as the major health emergency in a century. Despite the course of the disease appearing to be mild in many cases, a significant proportion of symptomatic patients develop pneumonia requiring hospitalisation or progress to manifest respiratory complications leading to intensive care treatment. Potential interventions for SARS-CoV2-associated pneumonia are being tested, some of which holding promise, but as of today none of these has yet demonstrated outstanding efficacy in treating COVID-19. In this article, we discuss fresh perspectives and insights into the potential role of immune dysregulation in COVID-19 as well as similarities with systemic inflammatory response in sepsis and the rationale for exploring novel treatment options affecting host immune response.

AB - The novel coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is sorely testing health care systems and economies around the world and is rightly considered as the major health emergency in a century. Despite the course of the disease appearing to be mild in many cases, a significant proportion of symptomatic patients develop pneumonia requiring hospitalisation or progress to manifest respiratory complications leading to intensive care treatment. Potential interventions for SARS-CoV2-associated pneumonia are being tested, some of which holding promise, but as of today none of these has yet demonstrated outstanding efficacy in treating COVID-19. In this article, we discuss fresh perspectives and insights into the potential role of immune dysregulation in COVID-19 as well as similarities with systemic inflammatory response in sepsis and the rationale for exploring novel treatment options affecting host immune response.

KW - Checkpoint inhibitors

KW - Covid-19

KW - Cytokine storm

KW - Immune dysregulation

KW - Inflammatory receptors

KW - Sepsis

UR - http://www.scopus.com/inward/record.url?scp=85085506657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085506657&partnerID=8YFLogxK

U2 - 10.1007/s00011-020-01366-6

DO - 10.1007/s00011-020-01366-6

M3 - Article

AN - SCOPUS:85085506657

JO - Inflammation Research

JF - Inflammation Research

SN - 1023-3830

ER -